Pear Therapeutics Announces Publication of Data Analysis Showing Real-World Cost Impact of ReSET-O®

Pear Therapeutics, Inc., today announced publication of a new analysis demonstrating the real-world cost impact of reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD).